Research Article
Cancer Incidence in Egypt: Results of the National Population-Based Cancer Registry Program
Table 7
Incidence rates/100,000 population of individual cancer sites in Lower, Middle, and Upper Egypt: females.
| | Primary site | Lower Egypt | Middle Egypt | Upper Egypt | | 2009–2011 | 2009 | 2008 | | Crude | ASR | % | Crude | ASR | % | Crude | ASR | % |
| | Lip | 0.3 | 0.4 | 0.26% | 0.2 | 0.4 | 0.24% | 0.0 | 0.0 | 0.00% | | Tongue | 0.3 | 0.5 | 0.26% | 0.3 | 0.5 | 0.34% | 0.2 | 0.2 | 0.16% | | Mouth | 0.1 | 0.2 | 0.09% | 0.5 | 0.8 | 0.53% | 0.9 | 1.5 | 0.80% | | Salivary glands | 0.2 | 0.2 | 0.13% | 0.3 | 0.4 | 0.29% | 0.2 | 0.4 | 0.16% | | Tonsil | 0.1 | 0.1 | 0.04% | 0.0 | 0.1 | 0.05% | 0.0 | 0.0 | 0.00% | | Other oropharynx | 0.0 | 0.0 | 0.00% | 0.1 | 0.1 | 0.10% | 0.2 | 0.3 | 0.16% | | Nasopharynx | 0.1 | 0.1 | 0.04% | 0.0 | 0 | 0.05% | 0.2 | 0.2 | 0.16% | | Hypopharynx | 0.0 | 0.0 | 0.00% | 0.4 | 0.4 | 0.38% | 0.6 | 0.9 | 0.48% | | Pharynx unspec. | 0.0 | 0.0 | 0.00% | 0.0 | 0.0 | 0.05% | 0.0 | 0.0 | 0.00% | | Esophagus | 0.9 | 1.2 | 0.65% | 1.2 | 1.9 | 1.25% | 1.1 | 1.6 | 0.96% | | Stomach | 2.3 | 3.2 | 1.73% | 1.2 | 1.8 | 1.25% | 1.9 | 3.1 | 1.60% | | Small intestine | 0.3 | 0.5 | 0.22% | 0.4 | 0.6 | 0.43% | 0.6 | 0.9 | 0.48% | | Colon | 3.0 | 4.2 | 2.30% | 2.2 | 3.2 | 2.31% | 2.4 | 3.5 | 2.08% | | Rectum | 0.9 | 1.0 | 0.65% | 1.0 | 1.2 | 1.01% | 0.7 | 1.3 | 0.64% | | Anus | 0.1 | 0.1 | 0.04% | 0.1 | 0.2 | 0.14% | 0.2 | 0.3 | 0.16% | | Liver | 21.6 | 32.6 | 16.37% | 8.6 | 13.7 | 8.95% | 6.0 | 8.7 | 5.12% | | Gallbladder and so forth | 0.5 | 0.5 | 0.35% | 0.6 | 0.9 | 0.58% | 1.9 | 3.1 | 1.60% | | Pancreas | 2.1 | 3.2 | 1.60% | 0.9 | 1.4 | 0.91% | 1.7 | 2.3 | 1.44% | | Nose, sinuses and so forth | 0.3 | 0.5 | 0.26% | 0.1 | 0.2 | 0.14% | 0.2 | 0.2 | 0.16% | | Larynx | 0.2 | 0.3 | 0.17% | 0.3 | 0.4 | 0.29% | 0.4 | 0.7 | 0.32% | | Trachea, Bronchus, Lung | 3.7 | 5.3 | 2.82% | 2.2 | 3.1 | 2.26% | 2.4 | 3.8 | 2.08% | | Other Thoracic organs | 0.6 | 0.8 | 0.43% | 0.5 | 0.7 | 0.48% | 0.0 | 0.0 | 0.00% | | Bone | 2.0 | 2.3 | 1.52% | 1.8 | 2.4 | 1.92% | 3.4 | 4.4 | 2.88% | | Melanoma of skin | 0.2 | 0.3 | 0.17% | 0.0 | 0.1 | 0.05% | 0.0 | 0.0 | 0.00% | | Other skin | 1.7 | 2.4 | 1.26% | 1.0 | 1.5 | 1.06% | 1.9 | 3.1 | 1.60% | | Mesothelioma | 0.3 | 0.3 | 0.22% | 0.2 | 0.3 | 0.24% | 0.4 | 0.7 | 0.32% | | Kaposi sarcoma | 0.0 | 0.0 | 0.00% | 0.0 | 0.1 | 0.05% | 0.0 | 0.0 | 0.00% | | Connective, Soft tissue | 2.3 | 2.6 | 1.78% | 0.4 | 0.6 | 0.38% | 1.9 | 2.2 | 1.60% | | Breast | 43.8 | 53 | 33.22% | 25.8 | 35.6 | 26.84% | 45.3 | 64.5 | 38.72% | | Vulva | 0.0 | 0.0 | 0.00% | 0.3 | 0.4 | 0.34% | 0.0 | 0.0 | 0.00% | | Vagina | 0.1 | 0.2 | 0.09% | 0.1 | 0.2 | 0.14% | 0.6 | 1.0 | 0.48% | | Cervix Uteri | 1.7 | 2.4 | 1.26% | 1.0 | 1.5 | 1.06% | 0.6 | 0.9 | 0.48% | | Corpus Uteri | 0.6 | 0.9 | 0.43% | 0.6 | 0.9 | 0.67% | 1.7 | 2.9 | 1.44% | | Uterus unspec. | 3.7 | 5.3 | 2.77% | 1.0 | 1.3 | 1.06% | 2.4 | 3.8 | 2.08% | | Ovary | 5.1 | 6.4 | 3.90% | 3.6 | 5.0 | 3.75% | 7.1 | 10.2 | 6.08% | | Other female genital | 0.0 | 0.0 | 0.00% | 0.0 | 0.1 | 0.05% | 0.4 | 0.6 | 0.32% | | Placenta | 0.0 | 0.0 | 0.00% | 0.0 | 0.0 | 0.05% | 0.2 | 0.2 | 0.16% | | Kidney | 1.1 | 1.6 | 0.87% | 1.2 | 1.8 | 1.25% | 0.7 | 1.1 | 0.64% | | Renal pelvis | 0.2 | 0.3 | 0.17% | 0.2 | 0.3 | 0.19% | 0.2 | 0.2 | 0.16% | | Ureter | 0.0 | 0.0 | 0.00% | 0.0 | 0.0 | 0.00% | 0.0 | 0.0 | 0.00% | | Bladder | 3.7 | 5.9 | 2.77% | 3.1 | 4.9 | 3.27% | 3.6 | 5.7 | 3.04% | | Other urinary organs | 0.1 | 0.1 | 0.04% | 0.0 | 0.0 | 0.00% | 0.0 | 0.0 | 0.00% | | Eye | 0.1 | 0.1 | 0.04% | 0.3 | 0.5 | 0.34% | 0.2 | 0.2 | 0.16% | | Brain, Nervous tissue | 5.8 | 7.4 | 4.42% | 7.4 | 11.1 | 7.70% | 2.4 | 2.9 | 2.08% | | Thyroid | 5.1 | 5.4 | 3.90% | 1.6 | 2.1 | 1.64% | 3.6 | 4.2 | 3.04% | | Adrenal gland | 0.2 | 0.3 | 0.17% | 0.2 | 0.3 | 0.24% | 0.2 | 0.2 | 0.16% | | Other endocrine | 0.1 | 0.0 | 0.04% | 0.5 | 0.7 | 0.53% | 0.2 | 0.2 | 0.16% | | Hodgkin disease | 1.0 | 0.7 | 0.74% | 1.0 | 1.0 | 1.01% | 0.9 | 0.9 | 0.80% | | Non-Hodgkin lymphoma | 5.4 | 6.7 | 4.11% | 4.2 | 5.8 | 4.43% | 2.6 | 3.8 | 2.24% | | Immunoproliferative dis. | 0.0 | 0.0 | 0.00% | 0.0 | 0.0 | 0.00% | 0.0 | 0.0 | 0.00% | | Multiple myeloma | 0.7 | 0.9 | 0.52% | 0.1 | 0.3 | 0.14% | 0.2 | 0.0 | 0.16% | | Lymphoid leukemia | 1.0 | 1.1 | 0.74% | 1.2 | 1.6 | 1.25% | 1.5 | 1.6 | 1.28% | | Myeloid Leukemia | 0.9 | 1.1 | 0.65% | 1.7 | 2.0 | 1.78% | 2.2 | 3.3 | 1.92% | | Leukemia unspec. | 1.8 | 2.4 | 1.34% | 1.6 | 2.0 | 1.68% | 1.9 | 2.3 | 1.60% | | Other & unspecified | 5.9 | 8.2 | 4.46% | 14.3 | 15.5 | 14.86% | 9.2 | 12.9 | 7.84% |
| | All sites Total | 131.7 | 173.3 | 100.00% | 95.9 | 132.1 | 100.00% | 116.9 | 167.1 | 100.00% | | All sites but C44# | 130.1 | 170.9 | 98.74% | 94.9 | 130.7 | 98.94% | 115.1 | 163.9 | 98.40% |
|
|
Incidence rates do not include nonmelanoma skin cancer.
|
